IQVIA Holdings Inc. (NYSE:IQV) Receives $249.05 Consensus Price Target from Analysts

IQVIA Holdings Inc. (NYSE:IQV) has earned an average rating of “Moderate Buy” from the twenty-one research firms that are presently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $249.05.

Several brokerages recently commented on IQV. Morgan Stanley upped their target price on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a report on Monday, February 10th. JPMorgan Chase & Co. reduced their target price on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. UBS Group reduced their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Finally, BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd.

IQVIA Stock Performance

IQVIA stock opened at $186.80 on Monday. The business has a 50 day moving average of $195.71 and a 200-day moving average of $209.36. IQVIA has a 1 year low of $179.28 and a 1 year high of $256.29. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market capitalization of $32.93 billion, a P/E ratio of 24.91, a P/E/G ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities research analysts predict that IQVIA will post 10.84 earnings per share for the current year.

Hedge Funds Weigh In On IQVIA

A number of institutional investors have recently modified their holdings of IQV. Synergy Asset Management LLC acquired a new position in shares of IQVIA during the fourth quarter worth approximately $33,000. Avior Wealth Management LLC raised its position in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares during the last quarter. GKV Capital Management Co. Inc. purchased a new stake in IQVIA in the 4th quarter valued at $39,000. Lee Danner & Bass Inc. purchased a new stake in IQVIA in the 4th quarter valued at $44,000. Finally, Zions Bancorporation N.A. raised its position in IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after buying an additional 85 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.